To assess the efficacy and safety of orforglipron compared with placebo in maintaining body weight reduction after treatment with tirzepatide or semaglutide in participants with obesity, focusing on primary and secondary endpoints.
Key Findings:
Participants maintained 74.7% of body weight reduction with orforglipron compared to 49.2% with placebo (P < 0.001), indicating a significant treatment effect.
43.7% of participants on orforglipron maintained ≥80% of body weight reduction compared to 16.4% with placebo (P < 0.001), highlighting the efficacy of orforglipron.
Overall, participants on orforglipron maintained 74.4% of body weight reduction versus 49.7% with placebo (P < 0.001), reinforcing the treatment's effectiveness.
Interpretation:
Orforglipron is effective in maintaining weight loss achieved through prior injectable therapies, demonstrating significant advantages over placebo, which may enhance patient adherence to obesity management.
Limitations:
The study duration may not capture long-term effects of orforglipron, and further studies are needed to assess durability.
The population may not represent all demographics affected by obesity, limiting generalizability.
Conclusion:
Orforglipron shows promise as a maintenance therapy for weight loss, potentially addressing barriers associated with injectable obesity management medications and improving patient adherence.
by Louis J. Aronne, Deborah B. Horn, Carel W. le Roux, Ariana M. Chao, Wayne Ho, Bruno Halpern, Ryan Griffin, Cathy Xie, Elisa Gomez Valderas, Clare J. Lee, Anderson Ribeiro, David M. Hyman, Leonard Glass, Neena Xavier
